Back to Search
Start Over
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa
- Source :
- Antimicrob Agents Chemother
- Publication Year :
- 2022
- Publisher :
- American Society for Microbiology, 2022.
-
Abstract
- The ability of broad-spectrum β-lactamases to reduce the susceptibility to ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam (AZA), and cefiderocol (FDC) was evaluated both in Pseudomonas aeruginosa and in Escherichia coli using isogenic backgrounds. Although metallo-β-lactamases conferred resistance in most cases, except for AZA, several clavulanic-acid-inhibited extended-spectrum β-lactamases (PER, BEL, SHV) had a significant impact on the susceptibility to CZA, C/T, and FDC.
- Subjects :
- Pharmacology
Lactams
Microbial Sensitivity Tests
biochemical phenomena, metabolism, and nutrition
bacterial infections and mycoses
Ceftazidime
beta-Lactamases
Anti-Bacterial Agents
Cephalosporins
Aztreonam
Drug Combinations
Infectious Diseases
Mechanisms of Resistance
Pseudomonas aeruginosa
Escherichia coli
polycyclic compounds
Humans
bacteria
Pharmacology (medical)
beta-Lactamase Inhibitors
Azabicyclo Compounds
Escherichia coli Infections
Subjects
Details
- ISSN :
- 10986596 and 00664804
- Volume :
- 66
- Database :
- OpenAIRE
- Journal :
- Antimicrobial Agents and Chemotherapy
- Accession number :
- edsair.doi.dedup.....be90e0774bcdceb8f219cb60e917cb1d